Draft guidelines regarding excessive pricing of patented medicines released

By Nathaniel Lipkus and Yael Mansour ( November 23, 2022, 1:35 PM EST) -- Federal price controls for patented medicines have been part of Canadian law for approximately 35 years. The Patented Medicine Prices Review Board’s (PMPRB) mandate is to prevent excessive pricing of patented medicines. The scope of the PMPRB’s mandate, and the manner in which it sets excessive prices, have profound implications for which drugs enter Canada and how they are to be priced....